Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 2Plasma cell 1Lymphoid 1Head & Neck 1Gynecologic 1Gastrointestinal 1Breast 1

Conditions

Motor Activity 22Precursor Cell Lymphoblastic Leukemia-Lymphoma 12Lymphoma 11Lymphoma, Follicular 5Leukemia 5Leukemia, Lymphocytic, Chronic, B-Cell 4Breast Neoplasms 4Multiple Myeloma 3Lymphoma, Non-Hodgkin 3Obesity 2Neoplasms 2Hodgkin Disease 2Fatigue 2Cardiotoxicity 2Waldenstrom Macroglobulinemia 1Ventricular Dysfunction, Left 1Urogenital Neoplasms 1Thyroid Neoplasms 1Sarcopenia 1Pulmonary Disease, Chronic Obstructive 1Prostatic Neoplasms 1Parasomnias 1Overweight 1Ovarian Neoplasms 1Non-alcoholic Fatty Liver Disease 1Neoplasms, Plasma Cell 1Lymphoma, T-Cell, Cutaneous 1Lymphoma, B-Cell, Marginal Zone 1Lung Neoplasms 1Leukemia, Myeloid, Acute 1

Interventions

Filgrastim 5fludarabine phosphate 4Cyclophosphamide 4Antilymphocyte Serum 4Mycophenolic Acid 3Carboplatin 3pembrolizumab 2Tacrolimus 2Sirolimus 2Radiotherapy 2Peripheral Blood Stem Cell Transplantation 2Paclitaxel 2Methotrexate 2Drug Therapy 2Cyclosporine 2Busulfan 2valspodar 1tremelimumab 1thymoglobulin 1temsirolimus 1tanespimycin 1sargramostim 1poly ICLC 1liposomal doxorubicin 1ixabepilone 1interferon-alfa-1b 1glutamic acid diethyl ester 1fludarabine 1etoposide phosphate 1durvalumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Kidney Neoplasms × Exercise × Lymphoid × Clear all
NCT04000880 2025-06-12

AMPLIFY

University of Alabama at Birmingham

Phase NA Active not recruiting
603 enrolled
BreastGastrointestinalGenitourinaryGynecologicHead & NeckLymphoidPlasma cell

Breast Neoplasms, Kidney Neoplasms, Lymphoma, Non-Hodgkin, Motor Activity, Multiple Myeloma, Ovarian Neoplasms, Prostatic Neoplasms, Thyroid Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡